Maxcyte (MXCT) Assets Average (2021 - 2026)

Maxcyte (MXCT) has reported Assets Average for 6 consecutive years, with $189.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 15.69% year-over-year to $189.6 million in Q2 2026; TTM through Jun 2026 was $189.6 million, a 15.69% decrease from a year earlier, with the FY2025 full-year figure at $221.0 million, down 12.95% from the prior year.
• Assets Average was $189.6 million for Q2 2026 at Maxcyte, down from $198.5 million in the prior quarter.
• Over five years, Assets Average peaked at $290.4 million in Q2 2022 and troughed at $189.6 million in Q2 2026.
• A 5-year average of $251.9 million and a median of $258.9 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 55.38% in 2022 and slipped 15.69% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $286.5 million in 2022, then slipped by 6.64% to $267.5 million in 2023, then slipped by 8.77% to $244.0 million in 2024, then fell by 14.77% to $208.0 million in 2025, then declined by 8.86% to $189.6 million in 2026.
• The last three Assets Average figures came in at $189.6 million (Q2 2026), $198.5 million (Q1 2026), and $208.0 million (Q4 2025), per Business Quant data.